Imris Receives Health Canada Approval for AccuTrack(TM)
WINNIPEG, Aug. 4, 2011 /PRNewswire/ – IMRIS Inc. (NASDAQ: IMRS) (TSX: IM)
(“IMRIS” or the “Company”) today announced that it has received a
Health Canada medical device license for AccuTrack(TM) the Company’s 3D
image guidance tool for use in IMRIS neurosurgery suites.
AccuTrack(TM) represents a significant enhancement to the IMRIS image
guided therapy suites. The new software-enabled capability aids
surgeons in critical decision making by utilizing an ergonomic
lightweight probe to quickly and accurately localize target anatomy
before; and at any time during a neurosurgical procedure. This is
achieved by enabling automatic registration of patient anatomy to
intraoperative MR images, rather than using the standard manual image
registration to preoperative MR images which do not accommodate brain
shift and may therefore be less accurate.
IMRIS suites are designed to provide timely imaging information to
assist clinicians in making better decisions during procedures for
improved patient outcomes. The IMRIS system allows a high field MR
scanner to move into an operating room on demand before, during and
after procedures without moving the patient. The patient is not
required to be transported for scanning, thus optimum patient
positioning is always maintained. Clinical workflow and access to the
patient is not impacted and the MR scanner is removed completely from
the operating room when imaging is complete. This ensures a high degree
of safety in the surgical environment and for the patient.
AccuTrack(TM) previously received CE Mark regulatory approval in Europe and
is FDA 510(k) Pending in the United States.
IMRIS (NASDAQ: IMRS; TSX: IM) is a global leader in providing image
guided therapy solutions. These solutions feature fully integrated surgical and interventional
suites that incorporate magnetic resonance, fluoroscopy and computed tomography to deliver on demand
imaging during procedures. The Company’s systems serve the neurosurgical,
cardiovascular and neurovascular markets and have been selected by leading medical institutions around
SOURCE IMRIS Inc.